IRON Disc Medicine, Inc.

Q3 2025 10-Q

Filed: Nov 6, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Disc Medicine, Inc. (IRON) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• No quarterly revenue or YoY change data disclosed in provided section
• No profitability or margin figures presented in provided text

+3 more insights

Risk Factors

• New risk: Rapid NDA filing for bitopertin in EPP and XLP in Sept 2025 with FDA's National Priority Voucher accelerates review to 1-2 months, increasing near-term regulatory pressure
• Updated financial risk: Entered $200M senior secured Hercules Loan in Nov 2024 with maturity Dec 2029, including restrictive covenants and minimum qualified cash requirements

+3 more insights

Quarterly Financial Summary
XBRL

Net Income

-$62M

▼ -134.3% YoY▼ -12.8% QoQ

ROE

-10.9%

Total Assets

$630M

EPS (Diluted)

$-1.78

▼ -104.6% YoY▼ -11.9% QoQ

Operating Cash Flow

-$48M

▼ -175.3% YoY▲ +0.2% QoQ

Source: XBRL data from Disc Medicine, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Disc Medicine, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.